Literature DB >> 20552588

Clinostatic hypertension and orthostatic hypotension.

Alfonso Lagi1, Simona Spini.   

Abstract

BACKGROUND: The association of clinostatic hypertension (CH) and orthostatic hypotension (OH) is described as the "Hyp-Hyp phenomenon," and it has been found in about 5.5% of hypertensive patients and in up to 50% of patients with OH. The importance of CH/OH in clinical practice is mainly due to the presence of troublesome symptoms, end-organ damage, and difficulties in its clinical management. HYPOTHESIS: The review focuses on the clinical problem of CH and review the international literature for the best management, including the diagnostic work-up and the taylored treatment for this kind of patients.
METHODS: A systematic review of the literature was conducted through MEDLINE research to focus the main controversial issues about CH/OH. Included topics: (1) the diagnostic work-up, (2) the association with dysautonomic failure and syncope, and (3) the treatment options and prevention of end-organ damage.
RESULTS: Current standard reference for OH diagnosis includes functional assessment of the cardiac vagal nervous system and the sympathetic adrenergic system. The association with dysautonomic failure and with syncope needs further investigation. Pharmacologic treatment of OH is aimed at controlling symptoms rather than restoring normotension. Midodrine is the only medication that has been put to multicenter placebo-controlled trial and subsequently approved by the U.S. Food and Drug Administration (FDA) for OH treatment. Short-acting oral antihypertensive agents at bedtime should be considered in patients with severe, sustained CH.
CONCLUSIONS: Data obtained from the literature review showed that clinical diagnosis of the Hyp-Hyp phenomenon is relatively simple, but it remains more difficult to establish the causal disease. In our opinion, it is advisable to define simple diagnostic standards for the selection of patients at risk of dysautonomic impairment so that a subsequent highly specific diagnostic work-up could be initiated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20552588      PMCID: PMC6652968          DOI: 10.1002/clc.20722

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  6 in total

1.  Orthostatic hypotension leading to recurrent syncope episodes in a hypertensive patient: Treatment with Tianma Gouteng Decoction.

Authors:  Yun-fei Wang; La Zhang
Journal:  Chin J Integr Med       Date:  2013-10-30       Impact factor: 1.978

2.  Prevalence, associations, and risk factors for orthostatic hypotension in medical, surgical, and trauma inpatients: an observational cohort study.

Authors:  Ar Kar Aung; Susan J Corcoran; Vathy Nagalingam; Eldho Paul; Harvey H Newnham
Journal:  Ochsner J       Date:  2012

3.  Association of cognitive dysfunction with neurocirculatory abnormalities in early Parkinson disease.

Authors:  Joong-Seok Kim; Yoon-Sang Oh; Kwang-Soo Lee; Yeong-In Kim; Dong-Won Yang; David S Goldstein
Journal:  Neurology       Date:  2012-09-12       Impact factor: 9.910

Review 4.  Management of Hypertension and Blood Pressure Dysregulation in Patients with Parkinson's Disease-a Systematic Review.

Authors:  Vasiliki Katsi; Ilias Papakonstantinou; Eirini Solomou; Alexios S Antonopoulos; Charalambos Vlachopoulos; Konstantinos Tsioufis
Journal:  Curr Hypertens Rep       Date:  2021-05-07       Impact factor: 5.369

5.  Carotid artery thickening and neurocirculatory abnormalities in de novo Parkinson disease.

Authors:  Joong-Seok Kim; Yoon-Sang Oh; Kwang-Soo Lee; In-Uk Song; In-Seok Park; Dong-Won Yang; Ja-Seong Koo; David S Goldstein
Journal:  J Neural Transm (Vienna)       Date:  2014-04-02       Impact factor: 3.575

6.  Early Signs of Autonomic Nervous System Imbalance in Children with High Cardiometabolic Risk.

Authors:  Irene Rutigliano; Salvatore Cringoli; Valeria Verrotti di Pianella; Pasquale Maccarone; Massimo Pettoello-Mantovani; Michele Sacco
Journal:  Turk Arch Pediatr       Date:  2022-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.